Description
Key facts
Cell type:A549,
Species or organism:Human,
Tissue:Lung,
Form:LiquidSee storage information,
Knockout validation:Sanger Sequencing,Western blot,
Mutation description:Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon 1,
Disease:Carcinoma
Product details:
We will provide viable cells that proliferate on revival.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-CBR1, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Western blot, Zygosity-Homozygous, Shipped at conditions-Dry Ice, Appropriate short-term storage conditions--196°C, Appropriate long-term storage conditions--196°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Cbr1 also known as carbonyl reductase 1 is an important enzyme in the reduction of carbonyl compounds to their alcohol forms. It weighs around 30 kDa and exhibits a wide expression across various tissues but is notably present in the liver and heart. The enzyme acts as a monomer and follows an NADPH-dependent mechanism for its action playing an important role in the detoxification of xenobiotics and the metabolism of endogenous compounds.
Biological function summary
Carbonyl reductase 1 functions in the metabolism of prostaglandins steroids and aromatic aldehydes. Cbr1 is not known to form part of a larger protein complex but acts independently to execute its enzymatic roles. It exhibits broad substrate specificity allowing it to reduce a variety of carbonyl groups which influences several physiological processes such as lipid metabolism and hormone synthesis.
Pathways
The enzyme plays an important role in the prostaglandin metabolic pathway where it reduces prostaglandin E2. Additionally Cbr1 interacts within the retinol metabolism pathway. In these pathways it functions alongside proteins such as aldo-keto reductases and aldose reductase sharing substrate specificity which impacts cellular responses and metabolic regulation.
Cbr1 influences the development of drug resistance in cancer therapy particularly in anthracycline-treated cancers due to its role in drug metabolism. It also associates with cardiovascular conditions where its metabolic activity might affect oxidative stress levels. Connections with other proteins such as superoxide dismutases link Cbr1 to oxidative stress response pathways impacting disease progression and therapy outcomes.
